Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Thursday, March 24, 2022 at 2 p.m. CET / 9 a.m. ET...

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “ AMF ”) General Regulation...

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the following upcoming...

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation...

Financing strengthens Company’s cash horizon Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that it has obtained €28.7M in non-dilutive financing...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the Company will participate in the following upcoming virtual investor conferences: ODDO BHF...

Partner Sanofi advances IPH6101/ SAR443579, a novel NKp46/CD16-based, CD123 targeted NK cell engager, to first-in-human clinical trial in relapsed/refractory AML, B-ALL or HR-MDS First molecule from...

First chemo-free triplet shows preliminary activity and an acceptable safety profile with low rate of discontinuation Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company...

Innate to present new Phase 2 data on the combination of monalizumab, cetuximab and durvalumab in head and neck cancer in an oral presentation ANKET TM to be highlighted in ESMO IO educational session...